HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
February 24 2022 - 8:35AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2022/1/7/hetryrevive.png)
HAVN Life
Secures Purchase Order for Controlled Substance Sale to Revive
Therapeutics Ltd. for Use in Clinical Research
The naturally
derived GMP psilocybin will be exported through distribution
partner Mycrodose Therapeutics Inc. to the University of
Wisconsin-Madison, Contract Research Organization for Revive
Therapeutics
Vancouver,
BC, February
24, 2022 -- InvestorsHub NewsWire -- HAVN Life
Sciences Inc. (CSE:
HAVN)
(OTC: HAVLF)
(FSE: 5NP)
(the "Company" or
"HAVN Life") a biotechnology
company pursuing standardized extraction of psychedelic
compounds for investigational
research as potential APIs to support brain
health and cognitive function, is
pleased to announce it has successfully secured a purchase order
for naturally derived psilocybin from their Canadian supply
partner, Revive
Therapeutics Ltd. (CSE:
RVV)
(OTC: RVVTF)
(FSE: 31R)
("Revive") for
use in clinical research studies. The Company previously signed
a
supply agreement with
Revive in October, 2021.
In
fulfilling of the purchase order, HAVN Life will export naturally
derived GMP psilocybin extract from its facility in Jamaica into
the U.S. through its distribution partner, Mycrodose
Therapeutics Inc. ("Mycrodose")
for use by the University of Wisconsin-Madison ("UW-Madison"), a
Contract Research Organization ("CRO") for Revive. This shipment of
naturally derived psilocybin will allow UW-Madison to conduct
research and formulation work to finalize dosing and delivery
mechanisms in support of various studies to be sponsored by Revive
using an oral-thin
and Hydra-gel delivery systems of psychedelics to treat mental
health disorders.
"We
are so pleased to be able to supply our naturally
derived, GMP psilocybin for this potentially ground-breaking
research related to addiction disorders," says HAVN Life CEO Tim
Moore. "It is our hope that research like this will help in the
push toward the rescheduling of Schedule I compounds like
psilocybin and psilocin,
making treatment more accessible and helping to ease the growing
mental health and addiction crisis we are facing today," he
adds.
"We
are excited to work with HAVN Life to move forward with our
investigational clinical trials including our project in Antigua",
says Revive CEO Michael Frank. He adds, "we are eager to advance
the science on botanically-derived ingredients such as psilocin and
psilocybin".
"Mycrodose
is very pleased to continue our efforts to progress the use of
therapies based on botanically-derived psilocybin products with
HAVN Life by expanding the use of psilocybin in research across the
United States. Our DEA authorization to legally distribute
psilocybin for authorized research purposes helps us facilitate the
ease and access of using this Schedule I substance by DEA-licensed
Universities, CROs, and other institutions in the United States,"
says
Chad Conner, Chief Executive Officer, Mycrodose
Therapeutics. "We
wish Revive Therapeutics and The University of Wisconsin-Madison
continued success as they further progress their clinical trials
investigation treatments," he adds.
Revive
Therapeutic Ltd. is a life sciences company focused on the research
and development of therapeutics for rare disorders and infectious
diseases. With its acquisition of Psilocin Pharma Corp. and
advancements of its novel oral-thin film delivery system of
psychedelic compounds, Revive is working to advance
psilocybin-based therapeutics for mental health and abuse
disorders.
Mycrodose
is one of only a few US-pharmaceutical companies that has been
authorized by the United States Drug Enforcement Agency ("DEA"),
State of California Attorney General's Research Advisory Board, and
The Food & Drug Administration ("FDA") to research and develop
a total of eight (8) Schedule I and III compounds. In addition, the
DEA has granted Mycrodose authorization to import and distribute
for resale the controlled substances of psilocybin and psilocin to
approved organizations for clinical trials, research and
development, and analytical purposes.
HAVN
Life's operations in Jamaica are facilitated by strategic
partnerships with
Hypha Wellness and P.A.
Benjamin Manufacturing Company to provide
cultivation and processing facilities for psilocybe
mushrooms.
###
On Behalf of The Board of
Directors
Tim Moore
Chief Executive
Officer
About HAVN
Life Sciences Inc.
HAVN Life Sciences
is a biotechnology company
pursuing standardized extraction of psychedelic compounds for
investigational research as potential APIs, the development of
natural health products, and innovative therapies to support brain
health and enhance the capabilities of the mind.
Through its research division,
HAVN Labs, the company has developed an end-to-end supply chain of
standardized, naturally derived psychedelic compounds for
investigational research in an effort to define the future of
modern medicine. HAVN Life offers a full range of high-quality
mushroom and plant extracts that help support immune function and
support a healthy lifestyle.
Purchase our plant-based Natural
Health Products and find out more at yourhavnlife.com,
and follow us on Facebook,
Twitter,
Instagram
and Youtube.
About Revive
Therapeutics Ltd.
Revive
Therapeutics Ltd. Therapeutics
Ltd is a life sciences company focused on the research and
development of therapeutics for infectious diseases and rare
disorders, and it is prioritizing drug development efforts to take
advantage of several regulatory incentives awarded by the FDA such
as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric
Disease designations. Currently, the Company is exploring the use
of Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
acquisition of Psilocin Pharma Corp., Revive is advancing the
development of Psilocybin-based therapeutics in various diseases
and disorders. Revive's cannabinoid pharmaceutical portfolio
focuses on rare inflammatory diseases and the company was granted
FDA orphan drug status designation for the use of Cannabidiol (CBD)
to treat autoimmune hepatitis (liver disease) and to treat ischemia
and reperfusion injury from organ transplantation.
About
Mycrodose Therapeutics Inc.
Mycrodose
Therapeutics Inc. is a U.S.-Based
pharmaceutical company headquartered in San Diego,
California specializing in the development of advanced drug
delivery systems utilizing DEA Schedule I & III drugs and other
compounds to treat cancer related conditions, mental health, and
cognitive degenerative diseases. The company believes that its
IP-Protected
Sustained Microdosing Technology™ is a
smarter and safer approach to delivering pharmaceutical compounds
to patients of all ages and allows for an expandable and scalable
business model.
Contact:
Investor Relations:
ir@havnlife.com
Media: savi@emergence-creative.com
Forward-Looking
Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws
relating to statements regarding the purchase order for naturally
derived psilocybin from Revive (the "Purchase
Order"),
the exportation naturally derived GMP psilocybin extract from the
Company's facility in Jamaica into the U.S. through Mycrodose (the
"Exportation")
and delivery of the naturally derived GMP psilocybin extract to
UW-Madison in order for UW-Madison to conduct research and
formulation work (the "Delivery and
Use"),
Revive's business, products and future of Revive's business,
Mycrodose's business, products and future of Mycrodose's business
and the Company's business, products and future of the Company's
business. Although the Company believes that the expectations
reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be
correct. Readers are cautioned not to place undue reliance on
forward-looking information. Such forward-looking statements are
subject to risks and uncertainties that may cause actual results,
performance and developments to differ materially from those
contemplated by these statements depending on, among other things,
the risks that the Purchase Order may not be completed as
contemplated, or at all, the risks that the Exportation may not be
completed as contemplated, or at all, risks that the Delivery and
Use may not be completed as contemplated, or at all, risks that
Revive's products and plan will vary from those stated in this news
release and Revive may not be able to carry out its business plans
as expected, risks that Mycrodose's products and plan will vary
from those stated in this news release and Mycrodose may not be
able to carry out its business plans as expected and risks that the
Company's products and plan will vary from those stated in this
news release and the Company may not be able to carry out its
business plans as expected. Except as required by law, the
Company expressly disclaims any obligation and does not intend to
update any forward-looking statements or forward-looking
information in this news release. Although the Company believes
that the expectations reflected in the forward-looking information
are reasonable, there can be no assurance that such expectations
will prove to be correct. The statements in this news release are
made as of the date of this release.
The CSE has
not reviewed, approved or disapproved the content of this press
release.
Havn Life Sciences (CE) (USOTC:HAVLF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Havn Life Sciences (CE) (USOTC:HAVLF)
Historical Stock Chart
From Aug 2023 to Aug 2024